Industry News (Acquisitions)

Promising Anticancer Agent in Phase II Trials Acquired

Published in Cancer Weekly, September 15th, 1997

SuperGen, Inc., San Ramon, California, announced it has acquired exclusive worldwide rights to a patented anti-cancer compound from the Stehlin Foundation for Cancer Research, Houston, Texas.

The drug, a topoisomerase I inhibitor which has been designated "RFS 2000" by the company, is patented and is a semi-synthetic derivative of a naturally-occurring plant alkaloid with cancer-killing properties. It is extracted from the bark and leaves of the Camptotheca acuminata tree, which is native to China.

RFS 2000 currently is in Phase II human trials for pancreatic cancer, for which Orphan Drug Status already has been obtained from the U.S. Food...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-09-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry